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Control based asthma management, comprising a continuous cycle of assessment, 1 
adjustment, and review of treatment response, is recommended by the Global Initiative for 2 
Asthma (GINA) guidelines (1). Objective measurement and documentation of asthma control 3 
in UK clinical practice is often poor. In the National Review of Asthma Deaths (UK), of the 4 
69% of patients who had an asthma review before their death, only 27% had any formal 5 
assessment of asthma control (2). Therefore, having a simple, but effective tool to detect 6 
changing severity of asthma is important. 7 
The Asthma Control Questionnaire (ACQ-6), is a widely used and well validated non-binary 8 
metric which strongly predicts future exacerbations(3)
 
. It demarcates between controlled (C), 9 
partially controlled (P), and uncontrolled (U), based on cut point scores of <0.75, ≥0.75<1.5, 10 
and ≥1.5 respectively (4). The asthma visual analogue scale (VAS) is a 10cm continuum 11 
indicating the overall symptom burden (5), and can be patient or physician administered. It 12 
has been demonstrated, in a large Japanese population to discriminate between GINA defined 13 
categories of C, P and U as <1.5cm, ≥1.5<7.19cm, and ≥7.19cm respectively (5). VAS has 14 
also been shown to be effective in adolescents at detecting changes in asthma symptoms 15 
reflecting more detailed multi-item asthma diaries (6). We have evaluated for the first time 16 
whether VAS correlates to ACQ-6, and if the predefined GINA cut points relates to ACQ-6 17 
defined levels of control.   18 
We retrospectively analysed n=84 patients who volunteered for asthma screening into clinical 19 
trials at the Scottish Centre for Respiratory Research. All patients gave written informed 20 
consent for their anonymised screening data to be used. Patients had to have a physician 21 
based asthma diagnosis for at least three months before attending screening, and be free from 22 
an asthma exacerbation requiring steroids for 3 months prior to screening. Patients completed 23 
basic spirometry (Micromedical, Chatham, U.K.), exhaled nitric oxide (FeNO, NIOX MINO, 24 
Circassia Ltd, UK) had their medical history and concomitant medications recorded, and 25 
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completed both ACQ-6 (Qoltech Ltd), and VAS questionnaires. As per Ohta et al. patients 26 
were asked to perform the VAS, and As per Ohta et al. patients were asked to “pPut a mark 27 
on the line below to indicate how much your symptoms bother you?”, with a 0-10cm line 28 
presented to the patient, 0cm= “not at all bothersome”, and 10cm= “extremely bothersome” 29 
(5). 30 
The average age of patients was 52 years, and 90% of patients were receiving inhaled 31 
corticosteroids (ICS) with a mean beclometasone dipropionate (BDP) equivalent dose of 32 
675µg/day. Of those on ICS 80% received a long acting beta-2 agonist (LABA) as a 33 
combination inhaler (ICS/LABA), 42% of those receiving ICS also received concomitant 34 
leukotriene receptor antagonist (LTRA), mean FeNO was 45ppb, mean forced expiratory 35 
volume in 1 second (FEV1) was 89% predicted; 63% of patients had a positive skin prick 36 
test, with the mean number of positive skin prick tests being 2.  37 
VAS correlated with ACQ-6, overall Spearman’s correlation was 0.62, P<0.001. Mean VAS 38 
levels for ACQ were: C (<0.75): 2.2cm (95% CI 1.35-3.06), P (≥0.75<1.5): 2.56cm (95% CI 39 
2.61-4.50), U (≥1.5): 5.27cm (95% CI 4.46-6.08) (Figure 1). VAS did not correlate (rs= 0.08, 40 
p=NS) with FeNO, or FEV1 % predicted (r=-0.18, p=NS).  41 
Between group differences for mean values comparing GINA defined VAS categories of C 42 
(n=22) vs P/U (n=62) showed a significant difference for ACQ: 0.57 vs 1.73 (p<0.0005), but 43 
not FEV1: 89% vs 89%, or FeNO: 32ppb vs 30ppb. 44 
Between group differences for mean values comparing ACQ defined categories of C (n=27) 45 
vs P/U (n=57) showed no significant difference for: FEV1: 91% vs 88% or FeNO 29ppb vs 46 
36ppb. ACQ score also did not correlate to FeNO (r= -0.06, p=NS). 47 
Receiver operator curve  analysis, using ACQ to compare C vs U/P revealed an optimal cut 48 
point for VAS of 1.95cm (AUC 0.8, sensitivity 88%, specificity 68%), comparing C vs U 49 
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revealed a VAS cut point of 3.5cm (AUC 0.7, sensitivity 66%, specificity 61%). Furthermore 50 
the GINA defined cut point of ≥7.19cm was associated with a sensitivity of 26% and 51 
specificity of 91%. 52 
Our data showed that VAS correlated with the overall ACQ-6 score, however the VAS cut 53 
points used to determine GINA defined control were not tailored to ACQ. The mean VAS of 54 
5.27 (95% CI 4.46-6.08) for patients with an ACQ≥1.5 was not only lower than the 7.19cm 55 
GINA cut point, but also the ROC suggested that a much lower VAS value (≥3.5cm) would 56 
optimally identify such patients. The corollary is that patients with a VAS≥3.5cm, should 57 
warrant further enquiry into their asthma control (e.g. using ACQ), and that VAS may only 58 
be considered a quick screening tool in a busy clinic. Furthermore VAS is sensitive to 59 
bronchodilation (7) and can be repeated daily (6). The benefit of a daily symptom score such 60 
as VAS is that it may obviate recollection errors from retrospective questionnaires (8), 61 
furthermore, in adolescents, asthma VAS has been evidenced as predictive of future asthma 62 
control at 6 months (6).   63 
The failure of VAS to correlate with FEV1 % predicted corresponds with data from primary 64 
care, where VAS did not correlate to peak expiratory flow (9), suggesting that a proportion of 65 
asthmatics do not reliably detect changes in their lung function. This has been evidenced 66 
previously in the context of acute bronchoconstriction (10). 67 
We acknowledge our study has limitations. Firstly, the sample size is small, and from a single 68 
site, therefore it may not represent the general asthma population. Secondly this was a 69 
retrospective analysis, which found that VAS cut points correlating to GINA defined asthma 70 
control were not the most suitable for ACQ defined asthma control. The VAS cut points 71 
assessed in our study, were from a large cross sectional Japanese population. However, it 72 
cannot be assumed that these cut points are generalizable to other regions. A prospective 73 
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study with a larger sample size, using the lower cut points derived from our ROC analysis 74 
would further clarify how sensitive VAS is at detecting levels of ACQ asthma control of C, P, 75 
U. Finally, the VAS is a snapshot of current control, whereas the ACQ is reflective of the 76 
previous week.  77 
We conclude that the GINA defined VAS cut off (≥7.19cm) is a poor predictor of control in 78 
relation to an ACQ≥1.5. Hence, further evaluation is required to define the VAS threshold in 79 
relation to control defined by ACQ rather than GINA, and also whether a decline in VAS 80 
correlates to a decline in ACQ, as change in control is arguably more important as current 81 
level.   82 
 83 
 84 
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Figure 1.  
Distribution of ACQ control categories relative to VAS levels. Vertical lines represent GINA 
defined cut points of control (1.5cm) and uncontrolled (7.19cm) asthma. 
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